{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}],"title":"Worst Grade 1 CRS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}],"title":"Worst Grade 2 CRS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Worst Grade 3 CRS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Worst Grade 4 CRS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Worst Grade 5 CRS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Worst Grade ≥ 3 CRS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Worst Grade 1 Neurologic Toxicities"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Worst Grade 2 Neurologic Toxicities"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"}]}],"title":"Worst Grade 3 Neurologic Toxicities"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Worst Grade 4 Neurologic Toxicities"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Worst Grade 5 Neurologic Toxicities"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42"}]}],"title":"Worst Grade ≥ 3 Neurologic Toxicities"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"TEAE was defined as any AE with onset on or after the start of treatment. CRS events were graded by Lee et al 2014. Grade 1 : No life threatening symptoms and require symptomatic treatment only; Grade 2: Symptoms require and respond to moderate intervention; Grade 3: Symptoms require and respond to aggressive intervention; Grade 4: Life-threatening symptoms and requirements for ventilator support or continuous venovenous hemodialysis (CVVHD), and Grade 5: Death. Neurologic toxicities were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1: Mild, asymptomatic or mild symptoms and intervention not indicated; Grade 2: Moderate and minimal, local or noninvasive intervention indicated; Grade 3: Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening and urgent intervention indicated; Grade 5: Death related to AE.","groups":[{"description":"Participants with relapsed or refractory transplant ineligible DLBCL, PMBCL, or TFL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0. Participants also received a prophylactic regimen of levetiracetam (750 mg orally or IV twice daily (BID) starting on Day 0) and tocilizumab (8 mg/kg IV over 1 hour (not to exceed 800 mg)) on Day 2).","id":"OG000","title":"Phase 2 (Safety Management Study): Cohort 3"}],"paramType":"NUMBER","populationDescription":"The Safety Analysis Set included all participants treated with any dose of axicabtagene ciloleucel.","reportingStatus":"POSTED","timeFrame":"First infusion date of axicabtagene ciloleucel up to last follow-up visit (maximum duration: 6.8 years)","title":"Phase 2 Safety Management Study (Cohort 3): Percentage of Participants With Treatment-Emergent Cytokine Release Syndrome (CRS) and Neurologic Toxicities by Severity Grades","type":"PRIMARY","unitOfMeasure":"percentage of participants"}